New York City-based Mount Sinai researchers have released a new report, “Hallmarks of Liver Cancer: Therapeutic Implications,” on the understanding and treatment of liver cancer.
The report, published April 16 in Cell, highlights key biological processes of liver tumors and links those processes to available treatment strategies. The study found that 45% of intrahepatic cholangiocarcinoma tumors contain genetic alterations that can be targeted with existing or emerging therapies, according to an April 16 news release from the health system.
The study was led by Josep Llovet, MD, PhD, a professor of medicine at Mount Sinai’s Icahn School of Medicine and director of the Liver Cancer Program at New York City-based Mount Sinai Tisch Cancer Center; and Daniela Sia, PhD, associate professor of medicine at the Icahn School of Medicine.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
